Bridgehead International Appoints Marcus Deans as Principal Consultant

London 07 September 2011 ...... Marcus Deans, an expert in European pharmaceutical market access, pricing and reimbursement,  has joined Bridgehead International’s London office as Principal Consultant.

Marcus is an international pharmaceutical executive with extensive practical and academic experience of strategic international marketing, gained over a 15 year industry career.  He has held  a number of leadership positions at both a Global and European level, having previously been Head of European CNS (Strategic Marketing) and Global Brand Director at Novartis, where he managed a number of brands through both launch and loss of exclusivity (LOE).

For the past two years Marcus has been a European Pricing and Market Access Consultant at Takeda, where he was responsible for developing the market access strategies across the pre-launch portfolio, in addition to developing strategies for the brands facing LOE. This involved pricing assessments, European launch sequencing, value assessments and payer research, core value dossier development and providing input into health economic modelling. Ultimately, his core responsibilities were to aid the development of market access processes and capabilities and to ensure alignment with commercial strategic goals.

Marcus has a B.Sc. degree in Medical Biotechnology and is a Chartered Marketer and a Senior Lecturer on both the professional and postgraduate diploma in Marketing (CIM).

Bridgehead International's CEO, Timothy Fitzgerald commented; “We are delighted to welcome Marcus to the company,” “He brings precisely the mix of expertise and experience that our clients need”.

Notes to editors:

About Bridgehead International

Bridgehead is a leading strategic healthcare consultancy group, providing a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain.

Bridgehead's mission is to work with commercial organisations, government agencies and the investment community to ensure that:

• Companies have the funding, structure and strategic focus to deliver high levels of innovation and financial return  
• Patients have rapid and broad access to new innovative medicines, medical devices and diagnostic tools, particularly in areas of high unmet need.

With over 50 consultants and 60 associates in Europe, North America and Asia, Bridgehead provides a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modelling and intellectual property skills and experience. 

Bridgehead is globally recognised for its expertise in:

• Market access strategy
• Pricing and reimbursement strategy
• Health economics and health technology assessment
• Opportunity evaluation
• Transaction support.

In 2007 and 2011, Bridgehead was honoured with The Queen’s Award for Enterprise, for outstanding achievement in international trade. The Queen’s Award for Enterprise is the highest honour that can be bestowed upon a UK company and is the UK’s top award for business performance.

In 2009, Bridgehead was voted UK Strategic Advisor of the Year – Healthcare, in the ACQ Finance Magazine’s Global Awards.

For more information about Bridgehead International, please see http://www.bridgehead.com

Contacts at Bridgehead International:

Sep 8, 2011